Bio-Techne Corp TECH
72.61
0.04
0.06%
as of 25 Sep
- Market cap
- $11.4B
- P/E
- 62.1×
Follow TECH
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
60.38 | 73.61 | 113.10 | 111.26 |
+8 more quarters Free account |
P/S ratio |
9.07 | 6.75 | 7.54 | 7.11 | |
P/FCF ratio |
41.86 | 30.30 | 41.09 | 38.60 | |
P/Operating CF |
115.48 | 94.27 | 111.21 | 313.52 | |
P/B ratio |
5.23 | 3.92 | 4.56 | 4.40 | |
Price to Tangible BV |
13.29 | 10.36 | 13.18 | 13.58 | |
EV/Sales |
9.03 | 6.75 | 7.62 | 7.25 | |
EV/EBITDA |
31.40 | 32.16 | 41.98 | 40.81 | |
EV/Operating CF |
37.55 | 27.71 | 37.16 | 35.09 | |
EV/FCF |
41.66 | 30.31 | 41.54 | 39.35 | |
Quick Ratio |
2.94 | 2.77 | 2.55 | 2.28 | |
Current Ratio |
4.55 | 4.49 | 4.54 | 4.22 | |
Net Debt/EBITDA |
(0.66) | (0.10) | 1.10 | 2.15 | |
Debt/Assets |
7.73% | 7.84% | 10.31% | 11.88% | |
Debt/Equity |
0.09 | 0.10 | 0.13 | 0.15 | |
Asset Turnover |
0.47 | 0.47 | 0.47 | 0.46 | |
Operating CF/Net income |
1.75 | 1.70 | 2.17 | 0.72 | |
Capex/Depreciation |
(0.35) | (0.38) | (0.24) | (0.22) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
7.46% | 7.53% | 7.82% | 8.46% | |
Selling, General and Administrative Expense of Revenue |
35.24% | 35.11% | 38.43% | 40.56% | |
Intangible Assets out of Total Assets |
0.49 | 0.51 | 0.52 | 0.53 | |
Share Based Compensation of Revenue |
1.63% | 3.37% | 4.72% | 4.08% | |
Graham Net Nets |
0.02 | 0.03 | 0.01 | 0.01 | |
Graham Number |
18.86 | 14.60 | 12.29 | 11.93 | |
Earnings Yield |
1.66% | 1.36% | 0.88% | 0.90% | |
Free Cash Flow Yield |
2.39% | 3.30% | 2.43% | 2.59% | |
Revenue per Share |
2.06 | 1.99 | 1.90 | 1.84 | |
Operating CF per Share |
0.61 | 0.55 | 0.53 | 0.18 | |
Capex per Share |
(0.05) | (0.06) | (0.04) | (0.03) | |
Free Cash Flow per Share |
0.56 | 0.50 | 0.49 | 0.14 | |
Cash per Share |
1.70 | 1.34 | 1.11 | 0.93 | |
Shareholders Equity per Share |
13.52 | 13.34 | 12.90 | 12.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
13.52 | 13.34 | 12.90 | 12.64 | |
Free Cash Flow |
86.94 | 77.58 | 76.49 | 22.22 | |
Working Capital |
580.70 | 534.77 | 497.01 | 464.96 | |
Capital Expenditures |
(8.48) | (9.09) | (5.92) | (5.36) | |
Net Current Asset Value |
265.90 | 222.75 | 125.72 | 49.17 | |
EV/EBIT |
43.54 | 53.15 | 79.20 | 80.19 | |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.02 | |
Net Profit Margin |
17.01% | 16.39% | 12.85% | 13.33% | |
Price to Operating Income |
43.74 | 53.13 | 78.35 | 78.68 | |
| Other line items | |||||
Average Receivables |
211.73 | 225.85 | 201.28 | 203.79 | |
Average Payables |
26.01 | 27.57 | 29.69 | 30.86 | |
Average Inventory |
192.60 | 196.13 | 196.91 | 194.11 | |
Average Assets |
2,572.30 | 2,597.43 | 2,596.56 | 2,631.08 | |
Average Common Equity |
2,013.51 | 2,051.66 | 2,044.74 | 2,052.23 |
Columns are period end dates